AOD-9604 (Advanced Obesity Drug) was originally developed by Professor Frank Ng at Monash University in Australia, with the intent of finding an anti-obesity drug that had the fat burning effects of human growth hormone (HGH) without the muscle-building effect.
Investigators at Monash University discovered that the fat-reducing effects of HGH appear to be controlled by a small region near one end of the HGH molecule. This region, which consists of amino acids 177-191, is less than 10% of the total size of the HGH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural HGH regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified HGH.
Studies have suggested that AOD-9604 has an ability to stimulate lipolytic (fat burning) and anti-lipogenic activity. Like Growth Hormone, AOD-9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (the transformation of fatty food materials into body fat) both in laboratory testing and in animals and humans. Recent clinical research studies have shown that AOD-9604 showed a reduction of body fat in the mid abdominal area in both obese, over-weight, and average built people.
In laboratory tests on fat cells from rodents, pigs, dogs, and humans, AOD-9604 released fat specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat cells, and enhanced the burning of fat. In rodents (rats and mice), AOD-9604 reduced body fat in obese animals but enhanced fat burning without changing food consumption or inducing growth (as it does not increase IGF levels) or any other unwanted HGH effects. However its efficacy in humans is still a matter for further research. In fact, some studies have shown that AOD-9604 does not cause significant changes in body composition in humans.
Other recent findings have shown, in addition to its fat loss properties, AOD-9604 possesses other regenerative properties associated with growth hormone. Currently, trials are underway to show the application of AOD-9604 in osteoarthritis, hypercholesterolemia, and bone and cartilage repair.
Results of oral glucose tolerance testing demonstrated that, in contrast with HGH, AOD-9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD-9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604.
120 – 500 mcg subcutaneous before bed, pulse 5 days on/ 2 days off or 4 weeks on/ 1 week off
AOD-9604 is generally well tolerated. Six randomized, double-blind, placebo-controlled trials were performed with AOD-9604. AOD-9604 displayed a very good safety and tolerability profile, indistinguishable from placebo. AOD-9604 did not result in any of the adverse effects associated with full-length HGH treatment.
AOD-9604 has an excellent safety profile, recently obtaining Human GRAS status in the USA.
The most common side effect reported during the study were headache, fatigue, hypoglycemia, dizziness, nasopharyngitis , cough. None of the side effects were of severe intensity.
As with all subcutaneous injections there is the possibility of an injection site reaction ( e.g. pain, bruising, redness, itching, or swelling)
- Heffernan M, et al. “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice” [pubmed] [pdf]
- Stier H, et al. “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans” Journal of Endocrinology and Metabolism, North America (2013) [web]